HBRM Herborium Group Inc (PK)

Herborium Group, Inc. (OTC BB: HBRM), a botanical therapeutics� company that develops, licenses and markets novel botanical-based medicinal products and related digital support content, today announced that it will present a comprehensive overview of its Company and highlight recent achievements at the upcoming Southern California Investment Association�s (SCIA) Small Cap Conference. Only twelve companies were qualified for this presentation. The Conference will be held Saturday, June 14, 2008 at the Orange County Airport Hilton located at 18800 MacArthur Boulevard, Irvine, CA. An agenda for the event, registration and attendance details, and information about the SCIA is available their website: http://www.sciaonline.org. Dr. Agnes P. Olszewski, president and CEO of Herborium, said, �I am looking forward to the SCIA Small Cap Conference and the opportunity it will provide to tell the Herborium story to an audience of investment professionals.� About SCIA Southern California Investment Association is a comprehensive national alliance of almost 200 member firms consisting of NASD broker/ dealers, institutional, investment and merchant bankers, investment advisor's, analysts, market makers, financial service managers, fund managers, venture capitalists, media and accredited investors from all over the US. This is a specialized and seasoned group that buys and invests in smaller issues of companies with proven management. Since year 2000 the organization has funded more than $100 million per year and supported and assisted hundreds of public companies. About Herborium Herborium Group, Inc., a botanical therapeutics� company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk,�ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The Company�s flagship product, is AcnEase� a proprietary, all natural product improving conditions associated with acne and Rosacea that affects over 50 million people in USA alone. The company also secured a pipeline of additional products in the areas dermatological needs, Prostate Health (BPH), Liver Diseases including Hepatitis and Cirrhosis, Women�s Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems; and energy restoration products for depletion of energy due to competitive sports, high-level stress, extensive sexual activities, as well as other conditions that are physically demanding on a long-term or temporary basis. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. Certain matters discussed in this press release are �forward-looking statements� intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company�s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company�s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company�s control. The factors discussed herein and expressed from time to time in the Company�s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company�s filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.